Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Abstract Pevonedistat (TAK924) is a Nedd8-activating enzyme inhibitor with preclinical activity in non-Hodgkin lymphoma (NHL). This open-label, Phase I, multicenter, investigator-sponsored study enrolled patients with relapsed/refractory (R/R) NHL and chronic lymphocytic leukemia (CLL). The primary...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Pallawi Torka, Swetha Kambhampati Thiruvengadam, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D. Lynne Smith, Alex F. Herrera, Stephen E. F. Spurgeon, Byung Park, Lionel D. Lewis, Francisco Hernandez-Ilizaliturri, Zheng Xia, Alexey V. Danilov
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Publishing Group 2023-01-01
Serie:	Blood Cancer Journal
Accesso online:	https://doi.org/10.1038/s41408-022-00763-w
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!